The role of prophylactic tamsulosin (Flomax®) ± dexamethasone in patients undergoing prostate I125 seed implants for prostate carcinoma: A randomized double-blind study

Basit Öğe Kaydı
dc.authorscopusid7101885688
dc.authorscopusid22979793100
dc.authorscopusid6701618392
dc.authorscopusid6603194571
dc.authorscopusid7403177451
dc.authorscopusid6603364045
dc.authorscopusid7003342295
dc.contributor.authorCarlson T.P.
dc.contributor.authorKaplan M.
dc.contributor.authorCiezki J.P.
dc.contributor.authorElshaikh M.
dc.contributor.authorReddy C.A.
dc.contributor.authorUlchaker J.
dc.contributor.authorAngermeier K.
dc.date.accessioned2024-06-12T10:28:44Z
dc.date.available2024-06-12T10:28:44Z
dc.date.issued2008
dc.description.abstractIntroduction: In this study, we aimed to evaluate the effectiveness of prophylactic dexamethasone added to tamsulosin (Flomax®) in reducing urinary symptoms after I125 prostate brachytherapy (PI) for prostate adenocarcinoma. Materials and Methods: A single institution, randomized, double blind, placebo controlled trial of patients undergoing PI for prostate adenocarcinoma comparing the use of prophylactic dexamethasone plus tamsulosin before PI versus placebo plus tamsulosin was conducted. Patients undergoing permanent PI, who were not taking tamsulosin or other alpha-blockers prior to PI were eligible for the trial. All patients were given tamsulosin (0.8 mg, orally once a day) and were randomized to receive either placebo or dexamethasone (4 mg per day for the first 10 days after PI and then 2 mg per day for 4 additional days). Tamsulosin use was started four days prior to PI and continued for 60 days. Urinary symptoms were assessed with the American Urologic Association (AUA) symptom index score. The questionnaire was administered prior to PI and then on a weekly basis for the first eight weeks after PI and again at weeks 10 and 12 after PI. The primary endpoint of the trial was change in the AUA score from baseline. Patients were taken off of the study if they developed urinary retention, had intolerable urinary symptoms, or wished to discontinue with the trial. Results: One-hundred patients were enrolled in the study. Ninety-four patients started the study and 72 completed all 12 weeks. Patients were evenly matched according to pre-treatment and post-treatment characteristics except with regard to pre-treatment AUA score: the dexamethasone group had a median score of 3 while the placebo group had a median score of 5 (p=0.0023). When comparisons were made between the groups relative to percent change in overall AUA score from baseline, there was a significant difference in favor of the placebo group (p=0.0030). Conclusion: The combination of prophylactic dexamethasone and tamsulosin yields worse post-operative symptoms than prophylactic tamsulosin alone.en_US
dc.identifier.endpage290en_US
dc.identifier.issn1300-5804
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-56549119806en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage285en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17391
dc.identifier.volume34en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.relation.ispartofTurk Uroloji Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdenocarcinoma; Brachytherapy; Dexamethasone; Prostate; Tamsulosinen_US
dc.titleThe role of prophylactic tamsulosin (Flomax®) ± dexamethasone in patients undergoing prostate I125 seed implants for prostate carcinoma: A randomized double-blind studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu